These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
471 related articles for article (PubMed ID: 32663575)
21. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Coperchini F; Chiovato L; Croce L; Magri F; Rotondi M Cytokine Growth Factor Rev; 2020 Jun; 53():25-32. PubMed ID: 32446778 [TBL] [Abstract][Full Text] [Related]
22. Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin. Alunno A; Carubbi F; Rodríguez-Carrio J RMD Open; 2020 May; 6(1):. PubMed ID: 32423970 [TBL] [Abstract][Full Text] [Related]
23. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996 [TBL] [Abstract][Full Text] [Related]
24. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Tufan A; Avanoğlu Güler A; Matucci-Cerinic M Turk J Med Sci; 2020 Apr; 50(SI-1):620-632. PubMed ID: 32299202 [TBL] [Abstract][Full Text] [Related]
25. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Soy M; Keser G; Atagündüz P; Tabak F; Atagündüz I; Kayhan S Clin Rheumatol; 2020 Jul; 39(7):2085-2094. PubMed ID: 32474885 [TBL] [Abstract][Full Text] [Related]
26. Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome. Caracciolo M; Macheda S; Labate D; Tescione M; La Scala S; Vadalà E; Squillaci R; D'Aleo F; Morabito A; Garreffa C; Marciano MC; Oliva EN Front Immunol; 2020; 11():1942. PubMed ID: 32983123 [TBL] [Abstract][Full Text] [Related]
27. Audio Interview: Tocilizumab and Covid-19. Rubin EJ; Baden LR; Morrissey S N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870 [No Abstract] [Full Text] [Related]
28. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2. Yao Z; Zheng Z; Wu K; Junhua Z Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527 [TBL] [Abstract][Full Text] [Related]
30. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19. Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269 [No Abstract] [Full Text] [Related]
31. Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality. Smetana K; Rosel D; BrÁbek J In Vivo; 2020; 34(5):3027-3028. PubMed ID: 32871847 [TBL] [Abstract][Full Text] [Related]
32. Targeting the NLRP3 Inflammasome in Severe COVID-19. Freeman TL; Swartz TH Front Immunol; 2020; 11():1518. PubMed ID: 32655582 [TBL] [Abstract][Full Text] [Related]
33. Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications. Pelaia C; Tinello C; Vatrella A; De Sarro G; Pelaia G Ther Adv Respir Dis; 2020; 14():1753466620933508. PubMed ID: 32539627 [TBL] [Abstract][Full Text] [Related]
34. Cytokine storm induced by SARS-CoV-2. Song P; Li W; Xie J; Hou Y; You C Clin Chim Acta; 2020 Oct; 509():280-287. PubMed ID: 32531256 [TBL] [Abstract][Full Text] [Related]
35. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561 [TBL] [Abstract][Full Text] [Related]
36. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. Luo W; Li YX; Jiang LJ; Chen Q; Wang T; Ye DW Trends Pharmacol Sci; 2020 Aug; 41(8):531-543. PubMed ID: 32580895 [TBL] [Abstract][Full Text] [Related]
37. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333 [TBL] [Abstract][Full Text] [Related]
38. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection. Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH Front Immunol; 2020; 11():1022. PubMed ID: 32574260 [TBL] [Abstract][Full Text] [Related]
39. A rationale for targeting the P2X7 receptor in Coronavirus disease 19. Di Virgilio F; Tang Y; Sarti AC; Rossato M Br J Pharmacol; 2020 Nov; 177(21):4990-4994. PubMed ID: 32441783 [TBL] [Abstract][Full Text] [Related]
40. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study. Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C Front Immunol; 2020; 11():581338. PubMed ID: 33123167 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]